BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Michael Rice Sells 11,461 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Michael Rice sold 11,461 shares of the firm’s stock in a transaction dated Tuesday, June 8th. The shares were sold at an average price of $35.54, for a total transaction of $407,323.94. Following the sale, the chief executive officer now owns 281,673 shares of the company’s stock, valued at $10,010,658.42. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Michael Rice also recently made the following trade(s):

  • On Thursday, June 10th, Michael Rice sold 11,461 shares of BioLife Solutions stock. The shares were sold at an average price of $36.47, for a total transaction of $417,982.67.
  • On Friday, May 28th, Michael Rice sold 802 shares of BioLife Solutions stock. The shares were sold at an average price of $33.87, for a total transaction of $27,163.74.
  • On Tuesday, May 4th, Michael Rice sold 11,461 shares of BioLife Solutions stock. The shares were sold at an average price of $30.15, for a total transaction of $345,549.15.
  • On Thursday, May 6th, Michael Rice sold 11,461 shares of BioLife Solutions stock. The shares were sold at an average price of $30.41, for a total transaction of $348,529.01.
  • On Thursday, April 8th, Michael Rice sold 11,461 shares of BioLife Solutions stock. The shares were sold at an average price of $35.32, for a total transaction of $404,802.52.
  • On Thursday, April 1st, Michael Rice sold 10,149 shares of BioLife Solutions stock. The shares were sold at an average price of $36.53, for a total transaction of $370,742.97.
  • On Friday, March 26th, Michael Rice sold 3,809 shares of BioLife Solutions stock. The stock was sold at an average price of $35.01, for a total transaction of $133,353.09.

BLFS opened at $36.87 on Friday. The stock has a market capitalization of $1.49 billion, a P/E ratio of -44.42, a price-to-earnings-growth ratio of 30.12 and a beta of 1.45. The business has a 50 day simple moving average of $33.22. BioLife Solutions, Inc. has a 12-month low of $14.43 and a 12-month high of $47.97.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Wednesday, May 12th. The medical equipment provider reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.02). BioLife Solutions had a negative net margin of 39.34% and a negative return on equity of 0.35%. The firm had revenue of $16.85 million for the quarter, compared to analysts’ expectations of $15.60 million. Analysts forecast that BioLife Solutions, Inc. will post 0.12 EPS for the current fiscal year.

BLFS has been the subject of a number of research analyst reports. Maxim Group lifted their price target on shares of BioLife Solutions from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, March 23rd. TheStreet lowered shares of BioLife Solutions from a “c-” rating to a “d+” rating in a research note on Friday, May 7th. KeyCorp lifted their price target on shares of BioLife Solutions from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 23rd. Stephens lifted their price target on shares of BioLife Solutions from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 23rd. Finally, B. Riley lifted their price target on shares of BioLife Solutions from $35.50 to $61.00 in a research note on Wednesday, March 24th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. BioLife Solutions currently has an average rating of “Buy” and a consensus price target of $48.22.

A number of large investors have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in BioLife Solutions by 6.5% during the first quarter. BlackRock Inc. now owns 1,312,818 shares of the medical equipment provider’s stock valued at $47,262,000 after purchasing an additional 80,147 shares in the last quarter. Geneva Capital Management LLC purchased a new position in BioLife Solutions during the first quarter valued at approximately $37,191,000. Tower House Partners LLP purchased a new position in BioLife Solutions during the fourth quarter valued at approximately $18,872,000. Millennium Management LLC lifted its holdings in BioLife Solutions by 323.2% during the first quarter. Millennium Management LLC now owns 458,677 shares of the medical equipment provider’s stock valued at $16,512,000 after purchasing an additional 350,290 shares in the last quarter. Finally, Jennison Associates LLC bought a new stake in shares of BioLife Solutions during the fourth quarter valued at approximately $17,934,000. 63.35% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Further Reading: Earnings Per Share

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.